Aim-To study the value of serum holotranscobalamin II (holo-TCII) measurements in the differential diagnosis of macrocytosis. Methods-Holo-TCII concentrations were measured in serum samples from 50 healthy non-vegetarian subjects and 30 patients with macrocytosis, using a technique based on the adsorption of holo-TCII with amorphous, precipitated silica. Deoxyuridine (dU) suppression tests were performed on the bone marrow cells of all the patients. Haematological diagnoses were made using standard criteria.
healthy non-vegetarian subjects and 30 patients with macrocytosis, using a technique based on the adsorption of holo-TCII with amorphous, precipitated silica. Deoxyuridine (dU) suppression tests were performed on the bone marrow cells of all the patients. Haematological diagnoses were made using standard criteria. Results-The causes of macrocytosis were cobalamin (Cbl) deficiency due to pernicious anaemia or following partial gastrectomy (10 patients), dietary folate deficiency with/without Cbl deficiency (four patients), chronic alcoholism (four patients), myelodysplastic syndrome (five patients), treatment with methotrexate or azathioprine (three patients), and congenital dyserythropoietic anaemia (CDA) (four patients). Undetectable or low holo-TCII concentrations were found in all patients with Cbl deficiency and in some or all patients from each ofthe other diagnostic categories. There was also no correlation between the dU suppressed value and the holo-TCII concentration: all 15 patients with high dU suppressed values and nine of 15 with normal dU suppressed values, including four patients with CDA, had low holo-TCII concentrations. Conclusions-Measurements of serum holo-TCII concentrations by the silica adsorption method are not of value in the differential diagnosis of macrocytosis. Preliminary studies were carried out to determine the extent of removal of holo-TCI and holo-TCII from serum by synthetic amor-phous precipitated silica (Sipernat 283 LS) (PQ Corporation, Valley Forge, Philadelphia, USA). Normal serum was incubated with 2.5 ng 57Co-cyanocobalamin per ml (57Co-CNCbl; specific activity 10 gCi/0.05 ,ug; Amersham International) at 37°C for one hour and dialysed for 24 hours against phosphate buffered saline (57Co-CNCbl treated serum).
Either 30 mg silica powder or 300 gl of an aqueous slurry containing 30 mg silica was added to 1 ml of 57Co-CNCbl treated serum. The mixtures were vortexed, left at room temperature for 10 minutes, centrifuged at 5000 x g for 10 minutes and the supernatants removed. Either 800 gl of these supernatants or of silica unadsorbed 57Co-CNCbl treated serum was run on a Sephadex G-200 column as described by Bloomfield and Scott,9 collecting 4 ml fractions at a flow rate of 12 ml/hour, and the radioactivity in 1 ml of each fraction determined using a Wallac 80000 gamma counter.
To determine holo-TCII concentrations in serum samples, holo-TCII was removed from serum using a slurry containing 6 g silica (Sipernat 283 LS) in 100 ml distilled water; 250, gl of the slurry containing 15 mg silica was mixed with 500 gl serum, vortexed and left at room temperature for 10 minutes. The mixture was then centrifuged at 5000 x g for 10 minutes. The supernatant fluid was assayed for Cbl (that is, for holo-TCI and holo-TCIII concentrations) using the IMx method, allowing for the dilution caused by mixing with the silica slurry (multiplication factor for dilution, x1.49). Total serum Cbl concentrations were also measured simultaneously using the IMx method and the holo-TCII concentration calculated by subtracting the holo-TCI plus holo-TCIII concentration from the total serum Cbl concentration.
Results Figure 1 shows the distribution of radioactivity in the fractions collected by Sephadex G-200 chromatography; the data for the serum treated with silica slurry were corrected for dilution. It is evident that silica did not remove significant amounts of holo-TCI and holo-TCIII (that is, holo-haptocorrin) and removed most of the holo-TCII. In two experiments with silica powder, the percentage removal of holo-TCI was 0.9 and 0.5 and the percentage removal of holo-TCII was 89 and 88, respectively. In one experiment with silica slurry, the removal of holo-TCI and holo-TCII was 0% and 87.5%, respectively. the precision for holo-TCII measurements was less satisfactory, with a coefficient of variation of 17.7%; the total Cbl concentration in the serum sample studied in this way was 289 ng/l and its holo-TCII concentration was 43.9 ng/l. The serum holo-TCII concentrations in the 50 healthy adults were log normally distributed, with a median value of 87 ng/l and 95% reference limits of 12.9-544.7 ng/l. The serum holohaptocorrin concentrations were also log normally distributed, with a median value of 381 ng/l and 95% reference limits of 188-771 ng/l.
The eventual diagnoses in the 30 patients studied were: pernicious anaemia (nine patients); post-gastrectomy Cbl deficiency (one patient); dietary deficiency of folate or folate and Cbl (four patients); chronic alcoholism (four patients); myelodysplastic syndrome (MDS) (five patients); macrocytosis secondary to treatment with methotrexate for rheumatoid arthritis (two patients) or to treatment with azathioprine (one patient); and congenital dyserythropoietic anaemia (CDA) (four patients). In three of the patients with CDA, Cbl and folate independent megaloblastic erythropoiesis was the major abnormality present; the fourth patient had CDA type I.
Fifteen patients had low total serum Cbl Fraction number Figure 1 Radioactivity per ml offractions obtained by Sephadex G-200 chromatography of "7Co-CNCbl treated serum before and after reaction with silica powder or silica slurry.
Limited value ofserum holo-transcobalamin II measurements in diagnosis of macrocytosis Figure 2 illustrates the relation between total serum Cbl and holo-TCII concentrations in patients and controls. It is evident that there is a considerable overlap between the results in healthy subjects and patients and between the results in patients with high and normal deoxyuridine suppressed values.
Discussion
Three methodological difficulties were identified in the measurement of serum holo-TCII concentrations by the silica adsorption method. Firstly, the lower limit for the sensitivity of most currently used methods for the measurement of Cbl, including the IMx Cbl assay, is around 60 ng/l. Holo-TCII assays on serum samples giving a Cbl value for silica adsorbed serum below 60 ng/l will be unreliable. Secondly, treatment with silica does not result in the complete removal of holo-TCII; however, the extent of removal is high, being about 88%. Thirdly, the reproducibility of holo-TCII measurements was relatively poor, partly because holo-TCII measurements are calculated as a difference between two assay results, each with its own coefficient of variation. More accurate holo-TCII measurements on serum samples with a low total Cbl concentration would require the use of the Euglena gracilis microbiological assay, which can measure Cbl concentrations accurately down to 20 ng/l.'"
In the present study, all 10 patients with Cbl deficiency had undetectable concentrations of holo-TCII. However, undetectable or low concentrations were also found in patients with dietary folate deficiency, in one of the two patients on methotrexate and in a mixed group of nine patients with normal deoxyuridine suppressed values in which the diagnoses were chronic alcoholism, MDS or CDA. Thus, whereas a low holo-TCII concentration seems to be a common feature of a degree of Cbl deficiency which gives rise to macrocytosis and a high deoxyuridine suppressed value, it does not help in distinguishing between Cbl deficiency and other causes of macrocytosis.
TCII is synthesised by several cell types including hepatocytes, endothelial cells and ileal enterocytes.3 As the initial plasma half-life of human holo-TCII injected into humans and rabbits is short (about 60 minutes"' 12), holo-TCII must be in a very dynamic state. The concentration of holo-TCII in plasma would depend on a complex balance between the rate of removal of Cbl from plasma holo-TCII by various cell types and the rates of entry into the plasma of new pre-formed holo-TCII molecules or generation in the plasma of holo-TCII by the reaction of newly released Cbl with plasma apo-TCII. Newly absorbed Cbl seems to combine with apo-TCII within the enterocyte and enter the circulation as holo-TCII.3 A low holo-TCII concentration may therefore result from decreased absorption of Cbl in the terminal ileum, a reduced rate of release of Cbl from the liver and other tissues for binding to apo-TCII or an increased rate of clearance of holo-TCII by binding to specific receptors on haemopoietic and other cells, or by some other mechanism. Previous investigators have only considered the first of these possibilities. Consequently, they have interpreted low holo-TCII concentrations in patients without haematological or biochemical changes attributable to Cbl deficiency as evidence of negative Cbl balance of recent onset due to reduce intake or absorption of this vitamin. 4'5 Our finding of low holo-TCII concentrations in as many as 60% of patients with normal deoxyuridine suppressed values suggests that one or more of the other mechanisms mentioned above may also be important. In particular, the finding of low holo-TCII concentrations in all four patients with erythroid hyperplasia due to CDA, indicates that noticeably increased erythropoietic activity may be an important cause of low holo-TCII concentrations. The poor precision of serum holo-TCII concentrations when measured in different assay runs by current methods must also contribute to the high prevalence of apparently low holo-TCII concentrations.
